Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

If we're being frank, which is how we roll in the Rocket Report, some of Orbex's recent activity does not inspire confidence.

We warn of NIO's profitability challenges and reliance on external financing, making it a risky long-term investment. Read an ...